The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The prognostic and predictive implications of the 12-chemokine score in muscle invasive bladder cancer.
 
Logan Zemp
No Relationships to Disclose
 
Anders E. Berglund
No Relationships to Disclose
 
Jasreman Dhillon
No Relationships to Disclose
 
Ryan Putney
No Relationships to Disclose
 
Youngchul Kim
No Relationships to Disclose
 
Rohit K. Jain
Honoraria - Alphasights (I)
Consulting or Advisory Role - Pfizer; Seattle Genetics/Astellas; Taiho Oncology (I)
Speakers' Bureau - Seattle Genetics/Astellas
 
George Daniel Grass
No Relationships to Disclose
 
Jingsong Zhang
Honoraria - AstraZeneca/MedImmune; Merck; Sanofi
Consulting or Advisory Role - AstraZeneca/MedImmune; Bayer; Clovis oncology; Dendreon; Janssen Oncology; Seagen
Speakers' Bureau - AstraZeneca; Merck Sharp & Dohme; Sanofi
Research Funding - AstraZeneca/MedImmune (Inst)
 
Michael Adam Poch
No Relationships to Disclose
 
Julio Powsang
No Relationships to Disclose
 
Wade J. Sexton
No Relationships to Disclose
 
Scott Michael Gilbert
No Relationships to Disclose
 
Shari Pilon-Thomas
Stock and Other Ownership Interests - ntellectual Property related to the proliferation and expansion of tumor infiltrating lymphocytes (TILs), which has been licensed to Iovance Biotherapeutics
 
Jose Conejo-Garcia
Stock and Other Ownership Interests - Anixa Biosciences; Compass Therapeutics
Consulting or Advisory Role - Anixa Biosciences; Compass Therapeutics
 
Colin P.N. Dinney
Consulting or Advisory Role - FKD Therapies
Research Funding - National Cancer Institute
 
James J Mule
Leadership - Moffitt Cancer Center
Stock and Other Ownership Interests - ownership interest (including patents) in Fulgent Genetics, Inc., Aleta Biotherapeutics, Inc., Cold Genesys, Inc., Myst Pharma, Inc., and Tailored Therapeutics, Inc
Consulting or Advisory Role - CG Oncology; GammaDelta Therapeutics; Mersana; Morphogenesis; Myst Therapeutics; OncoPep; Tailored Therapeutics; Verseau Therapeutics
 
Roger Li
Consulting or Advisory Role - Bristol-Myers Squibb